Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen's Repatha India Trial Waiver Plan Trips Up

Executive Summary

Amgen's PCSK9 inhibitor Repatha, already constrained by payor pushbacks on prices in the West and awaiting outcomes data, now appears to be facing a challenge in India. A key Indian expert panel has turned down Amgen's request for a trial waiver for evolocumab, a move that could hold up launch plans with partner Dr Reddy's.

Advertisement

Related Content

Amgen-Dr Reddy's Build On India Alliance
Amgen Plugs Away On Repatha, With Hope For New Monthly Product
Dr Reddy's To Market Amgen Therapies In India
Amgen's Repatha Gets Broad EU Label, But FDA May Not Follow Suit

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register